Frontlight ResearchEarly access
CompletedPhase 2
Impact of Post-Traumatic Stress Disorder Treatment by Reconsolidation Therapy on Fibromyalgia Syndrome
Key facts
- Who runs it
- Centre Hospitalier Henri Laborit
- Where
- France2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 17 people enrolled
- Started
- 13 Aug 2021
- Ended
- 13 Jan 2025
- Type of study
- Interventional
- Treatments tested
- Propranolol
- Record updated
- 9 September 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Adult over 18 years old
- Diagnosis of fibromyalgia syndrome according to ACR 2016 criteria
- PCL-5 > 44 suggesting the presence of a comorbid post-traumatic stress disorder
- Meet the DSM-5 criteria for post-traumatic stress disorder secondary to exposure to a traumatic event according to DSM-5 criteria, both unique or repeated and regardless of the date or location of the traumatic event
- Pain relief treatment and/or psychotropic treatment stabilized for a period greater than or equal to two months
- Signature of a consent form
- Patient able to understand and read french
Who cannot take part
- Adverse reactions or previous intolerances to a beta blocker
- Current intake of a drug with potential contraindication with the propranolol, according to the summary of product characteristics of the propranolol
- Psychotic disorders
- Unstable bipolar disorder
- Patients with a systolic blood pressure < 100 mmHg or heart rate < 55 as established during the initial visit
- Significant anormal ECG
- Medical contraindication to taking propranolol
- Current intake of another beta blocker which can not be stopped during the protocol, regardeless the galenic
- Patient under legal protection, under guardianship or under curatorship
- Patient having suffered a head trauma for less than a year or with clinical symptoms and neurological sequelae
- Known severe suicide risk (MINI-S and medical exam)
- Current opioid addiction or alcohol dependence
- Patients treated for less than 2 months with antidepressants or painkillers
- Patients unafiliated to a social health care
- Woman who is pregnant or breast-feeding or whithout efficient contraception
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The aim of the study is to demonstrate a significant improvement in quality of life specific to patients with fibromyalgia syndrome in patients with fibromyalgia syndrome with comorbid posttraumatic stress disorder, treated with reconsolidation blockade.
Read full original descriptionShow less
Patients receive a treatment with propranolol associated with reconsolidation blockade of traumatic story once a week during 6 weeks, with evaluation at inclusion and at 3 months.
The group in the trial
- Treatment with reconsolidation therapyTreatment being tested
Patient will take propranolol once a week during 6 weeks. The dosage of propranolol: 1 mg/kg propranolol form: tablet
Treatment: Propranolol
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 9 September 2026